CMA fines pharma companies for restricting drug supplies

The UK’s antitrust watchdog has fined four pharmaceutical companies and a private equity group more than £35 million for agreeing to limit the supply of an anti-nausea tablet to the National Health Service, causing prices to rise by 700%.

Get unlimited access to all Global Competition Review content